Inhibition of human complement-dependent cell lysis by bovine aortic endothelial cells transfected with membrane-bound complement-regulatory factor (DAF and HRF20) gene using a retroviral vector

European Surgical Research

Volumn 28, Issue 6, 1996, Pages 440-446

  Hayashi, S ^a   Isobe, K ^a   Emi, N ^a   Yokoyama, I ^a   Okada, H ^b   Nakashima, I ^a   Takagi, H ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Complement; Endothelial cell; Gene engineering; Retroviral vector; Xenotransplantation

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR;

ANIMAL; ARTICLE; CATTLE; CYTOTOXICITY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; PHYSIOLOGY; RABBIT; RETROVIRUS; COMPLEMENT ACTIVATION; CYTOLYSIS; ENDOTHELIUM CELL; GRAFT REJECTION; PRIORITY JOURNAL; REGULATORY MECHANISM; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; CATTLE; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; RABBITS; RETROVIRIDAE; TRANSFECTION;

EID: 0029658128     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000129489     Document Type: Article

References (22)

1. Bach FH: Revisiting a challenge in transplantation: Discordant xeno-grafting. Hum Immunol 1991:30: 262-269.
2. Sachs DH, Bach FH: Immunology of xenograft rejection. Hum Immunol 1990:28:245-251.
3. Atkinson JP. Farries T: Separation of self from non-self in the complement system. Immunol Today 1987: 8:212-215.
4. Nicholson-Wcller A, March JP. Rosenfeld SI. Austen KF: Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983: 80:5066-5070.
5. Yamashita M. Ueda E. Kinoshita T: Inherited complement deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990:323:1184-1189.
6. Motoyama N. Okada N. Yamashina M. Okada H: Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59)gcnc. Eur J Immunol 1992: 22:2669-2673.
7. Brooimans RA. Van Wieringen PAM. Van Es LA, Daha MR: Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol 1992;22:3135-3140.
8. Brooimans RA, Van Der Ark AAJ. Tomita M, Van Es LA, Daha MR: CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol 1992: 22:791-797.
9. Platt JL. Vcrccllotti GM. Dalmasso AP. Matas AJ, Bolman RM, Naja-rian JS. Bach FH: Transplantation of discordant xenografts: A review of progress. Immunol Today 1990: 11:450-457.
10. Platt JL. Vcrcclloti GM. Lindman BJ, Bach FH: Release of heparan sulfate from endothelial cells. J Exp Med 1990:171:1363-1367.
11. Ryan US: Isolation, culture, and subculture of bovine pulmonary artery endothelial cells: Mechanical methods. Tissue Cult Methods 1986:10:3-5.
12. Ikezawa H, Nakabayashi T. Suzuki K. Nakajima M, Taguchi T. Taguchi R: Complete purification of phos-phatidylinositol-specific phcspholi-pase C from a strain of Bacillus lliuringiensis. J Biochem 1983:93: 1717-1719.
13. Asch AS. Kinoshita T, Jaffc EA, Nussenzweig V: Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 1986:163:221-226.
14. Nose M, Katoh M. Okada N. Kyo-goku M. Okada H: Tissue distribution of HRF20. a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 1990:70: 145-149.
15. Walter EL Roberts WL. Rosenberry TL, Ratnofl WD, Medof ME: Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-spe-cific phospholipase C cleavage. J Immunol 1990;144:1030-1036
16. Zhao J. Rollins SA. Mahcr SE, Bolhwell ALM, Sims PJ: Amplified gene expression in CD59-transfcctcd Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Client 1991:266: 13418-13422.
17. Ratnoff WD. Fearson DT, Austen KF: The role of antibody in the activation of the alternative complement pathway. Springer Semin Im-munopathol 1983;6:361-371.
18. Okada N, Yasuda T. Okada H: Antibody-mediated alternative complement pathway activation resists inhibition by sialoglycolipids. J Immunol 1985:134:3316-3319.
19. Robinson PJ: Phosphatidvlinositol membrane anchors and T-cell activation. Immunol Today 1991; 12: 35-41.
20. Davis LS. Patel SS, Atkinson JP. Lipsky PE: Decay-accelerating factor as a signal transducing molecule for human T cells. J Immunol 1988; 141:2246-2252.
21. Korty PE. Brando C, Shevach EM: CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol 1991:146: 4092-4097.
22. Vcnncker GT. Asghar SS: CD59: A molecule involved in antigen presentation as well as downregulation of membrane attack complex. Exp Clin Immunogenct 1992;9:33-47.